Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
This study has been completed.
First Posted: April 4, 2002
Last Update Posted: June 16, 2016
Information provided by (Responsible Party):
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Biogen:
Contacts and Locations
No Contacts or Locations Provided